Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03364413
Other study ID # GFHNRC217
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 17, 2018
Est. completion date March 2, 2018

Study information

Verified date December 2023
Source USDA Grand Forks Human Nutrition Research Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to test how the brain responds when individuals eat enjoyable foods such as chocolate. Eating certain foods can make one want to keep eating even when feeling full, caused by dopamine in the brain. The researchers believe this dopamine response can be measured by looking at the individual's eye.


Description:

With obesity at an all-time high, understanding eating behavior beyond physical need is a priority. Food reinforcement is driven by central dopamine activity. However, objective measurement of brain dopamine-related behavioral events is hindered by the lack of non-invasive, accessible techniques that are amenable to testing in a "naturalistic" environment. The goal of this project is to develop a non-invasive, accessible methodology to measure dopaminergic responses to food in a natural setting. This research will use a novel, hand-held electroretinograph (ERG) that does not require eye dilation and uses a skin electrode to measure retinal dopamine activity. Previous work establishes that retinal dopamine activity can be used as a proxy for central dopamine function. The ability to assess both subjective behavioral variables and central dopaminergic responses simultaneously will provide an ideal approach for innovative studies of the control of eating behavior.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date March 2, 2018
Est. primary completion date March 2, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: - body mass index 20-30 kg/m2 - free of any major illness or disease Exclusion Criteria: - food allergies - participation in a weight loss diet or exercise program - pregnancy - lactation - metabolic illness or disease (diabetes, renal failure, thyroid illness, hypertension) - eye illness or disease (narrow angle glaucoma, macular degeneration, retinal detachment, cataracts) - psychiatric, neurological or eating disorders (schizophrenia, depression, Parkinson's Disease, Huntington's Disease, cerebral palsy, stroke, epilepsy, anorexia nervosa or bulimia nervosa) - take prescription medications except for oral contraceptives or antihyperlipidemia agents

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Chocolate
Participants will be asked to taste commercially available chocolate varying in sugar, fat and percent cocoa (milk, 70%, 85% and 90% cocoa).

Locations

Country Name City State
United States USDA Grand Forks Human Nutrition Research Center Grand Forks North Dakota

Sponsors (2)

Lead Sponsor Collaborator
USDA Grand Forks Human Nutrition Research Center Drexel University

Country where clinical trial is conducted

United States, 

References & Publications (1)

Casperson SL, Lanza L, Albajri E, Nasser JA. Increasing Chocolate's Sugar Content Enhances Its Psychoactive Effects and Intake. Nutrients. 2019 Mar 12;11(3):596. doi: 10.3390/nu11030596. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Retinal dopamine response to oral stimuli Electroretinograph beta wave amplitude will increase in response to increases in the amount of sugar in the chocolate 30 minutes
Primary Psychoactive Effects Questionnaire in response to oral stimuli The number of positive responses on the Psychoactive Effects Questionnaire will increase in response to increases in the sugar content of the chocolate 30 minutes
Secondary Scores on the Binge Eating Scale will correlate with the retinal dopamine and Psychoactive Effect Questionnaire responses Individual changes in the retinal dopamine response and the number of positive responses on the Psychoactive Effects Questionnaire will correlate with individual scores on the Binge Eating Scale 30 minutes
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2